Literature DB >> 25617006

Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis.

Conrad C Weihl1, Robert H Baloh2, Youjin Lee3, Tsui-Fen Chou4, Sara K Pittman3, Glenn Lopate3, Peggy Allred2, Jennifer Jockel-Balsarotti3, Alan Pestronk3, Matthew B Harms3.   

Abstract

Sporadic inclusion body myositis (sIBM) has clinical, pathologic and pathomechanistic overlap with some inherited muscle and neurodegenerative disorders. In this study, DNA from 79 patients with sIBM was collected and the sequencing of 38 genes associated with hereditary inclusion body myopathy (IBM), myofibrillar myopathy, Emery-Dreifuss muscular dystrophy, distal myopathy, amyotrophic lateral sclerosis and dementia along with C9orf72 hexanucleotide repeat analysis was performed. No C9orf72 repeat expansions were identified, but; 27 rare (minor allele frequency <1%) missense coding variants in several other genes were identified. One patient carried a p.R95C missense mutation in VCP and another carried a previously reported p.I27V missense mutation in VCP. Mutations in VCP cause IBM associated with Paget's disease of the bone (PDB) and fronto-temporal dementia (IBMPFD). Neither patient had a family history of weakness or manifested other symptoms reported with VCP mutations such as PDB or dementia. In vitro analysis of these VCP variants found that they both disrupted autophagy similar to other pathogenic mutations. Although no clear genetic etiology has been implicated in sIBM pathogenesis, our study suggests that genetic evaluation in sIBM may be clinically meaningful and lend insight into its pathomechanism.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Hereditary inclusion body myopathy; Inclusion body myositis; Myofibrillar myopathy; VCP

Mesh:

Substances:

Year:  2015        PMID: 25617006      PMCID: PMC4372452          DOI: 10.1016/j.nmd.2014.12.009

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  47 in total

1.  A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease.

Authors:  Michael A Gonzalez; Shawna M Feely; Fiorella Speziani; Alleene V Strickland; Matt Danzi; Chelsea Bacon; Youjin Lee; Tsui-Fen Chou; Susan H Blanton; Conrad C Weihl; Stephan Zuchner; Michael E Shy
Journal:  Brain       Date:  2014-08-14       Impact factor: 13.501

2.  GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM.

Authors:  Olavo M Vasconcelos; Raghavan Raju; Marinos C Dalakas
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

3.  Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.

Authors:  V Askanas; W K Engel; M Bilak; R B Alvarez; D J Selkoe
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

4.  Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations.

Authors:  Marjan Huizing; Goran Rakocevic; Susan E Sparks; Ioanna Mamali; Alexey Shatunov; Lev Goldfarb; Donna Krasnewich; William A Gahl; Marinos C Dalakas
Journal:  Mol Genet Metab       Date:  2004-03       Impact factor: 4.797

5.  Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis.

Authors:  V Askanas; W K Engel; R B Alvarez
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

6.  Consequences of mutations within the C terminus of the FHL1 gene.

Authors:  B Schoser; H H Goebel; I Janisch; S Quasthoff; J Rother; M Bergmann; W Müller-Felber; C Windpassinger
Journal:  Neurology       Date:  2009-08-18       Impact factor: 9.910

7.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.

Authors:  Giles D J Watts; Jill Wymer; Margaret J Kovach; Sarju G Mehta; Steven Mumm; Daniel Darvish; Alan Pestronk; Michael P Whyte; Virginia E Kimonis
Journal:  Nat Genet       Date:  2004-03-21       Impact factor: 38.330

8.  p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis.

Authors:  Anna Nogalska; Chiara Terracciano; Carla D'Agostino; W King Engel; Valerie Askanas
Journal:  Acta Neuropathol       Date:  2009-06-26       Impact factor: 17.088

9.  Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis.

Authors:  C R Harrington; J R Anderson; K K Chan
Journal:  Neurosci Lett       Date:  1995-01-02       Impact factor: 3.046

10.  A nuclear localization domain in the hnRNP A1 protein.

Authors:  H Siomi; G Dreyfuss
Journal:  J Cell Biol       Date:  1995-05       Impact factor: 10.539

View more
  24 in total

1.  ULK1 and ULK2 Regulate Stress Granule Disassembly Through Phosphorylation and Activation of VCP/p97.

Authors:  Bo Wang; Brian A Maxwell; Joung Hyuck Joo; Youngdae Gwon; James Messing; Ashutosh Mishra; Timothy I Shaw; Amber L Ward; Honghu Quan; Sadie Miki Sakurada; Shondra M Pruett-Miller; Tulio Bertorini; Peter Vogel; Hong Joo Kim; Junmin Peng; J Paul Taylor; Mondira Kundu
Journal:  Mol Cell       Date:  2019-04-09       Impact factor: 17.970

Review 2.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis.

Authors:  Anne-Katrin Güttsches; Stefen Brady; Kathryn Krause; Alexandra Maerkens; Julian Uszkoreit; Martin Eisenacher; Anja Schreiner; Sara Galozzi; Janine Mertens-Rill; Martin Tegenthoff; Janice L Holton; Matthew B Harms; Thomas E Lloyd; Matthias Vorgerd; Conrad C Weihl; Katrin Marcus; Rudolf A Kley
Journal:  Ann Neurol       Date:  2017-01-27       Impact factor: 10.422

4.  Targeted sequencing approach to identify genetic mutations in Nasu-Hakola disease.

Authors:  Jun-Ichi Satoh; Motoaki Yanaizu; Youhei Tosaki; Kenji Sakai; Yoshihiro Kino
Journal:  Intractable Rare Dis Res       Date:  2016-11

Review 5.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

6.  ACTA1-myopathy with prominent finger flexor weakness and rimmed vacuoles.

Authors:  Teerin Liewluck; Zhiyv Niu; Steven A Moore; Mohammad Alsharabati; Margherita Milone
Journal:  Neuromuscul Disord       Date:  2019-03-02       Impact factor: 4.296

7.  TMEM184b Promotes Axon Degeneration and Neuromuscular Junction Maintenance.

Authors:  Martha R C Bhattacharya; Stefanie Geisler; Sara K Pittman; Ryan A Doan; Conrad C Weihl; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  J Neurosci       Date:  2016-04-27       Impact factor: 6.167

8.  TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations.

Authors:  YouJin Lee; Per Harald Jonson; Jaakko Sarparanta; Johanna Palmio; Mohona Sarkar; Anna Vihola; Anni Evilä; Tiina Suominen; Sini Penttilä; Marco Savarese; Mridul Johari; Marie-Christine Minot; David Hilton-Jones; Paul Maddison; Patrick Chinnery; Jens Reimann; Cornelia Kornblum; Torsten Kraya; Stephan Zierz; Carolyn Sue; Hans Goebel; Asim Azfer; Stuart H Ralston; Peter Hackman; Robert C Bucelli; J Paul Taylor; Conrad C Weihl; Bjarne Udd
Journal:  J Clin Invest       Date:  2018-02-19       Impact factor: 14.808

Review 9.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

10.  215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13-15 November 2015, Heemskerk, The Netherlands.

Authors:  Teresinha Evangelista; Conrad C Weihl; Virginia Kimonis; Hanns Lochmüller
Journal:  Neuromuscul Disord       Date:  2016-05-30       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.